Abstract:
:We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having ≥ VGPR and 20% achieving a CR, similar to non +1q patients (p = .64). The median PFS from diagnosis with +1q was 2.1 years (95% CI: 1.2-not reached (NR)) vs 4.3 years (95% CI: 3.3 yrs-NR) without +1q (p = .003). Median OS from diagnosis was 4.4 years (95% CI: 2.9-NR) vs not reached, respectively (p = .005). On molecular analysis using the Foundation One Heme assay, the most common mutations seen in +1q patients included TP53 (38%) and KRAS (25%). Overall, gain of 1q portends worse PFS and OS which was not negated by auto HCT. Such patients will likely require additional therapy to improve their survival.
journal_name
Leuk Lymphomajournal_title
Leukemia & lymphomaauthors
Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SAdoi
10.1080/10428194.2016.1260126subject
Has Abstractpub_date
2017-08-01 00:00:00pages
1823-1831issue
8eissn
1042-8194issn
1029-2403journal_volume
58pub_type
杂志文章abstract::Colony stimulating factors reduce the duration of neutropenia following intensive chemotherapy in a variety of settings, but the advantages in the management of leukemia are inconclusive. The variations in clinical results and the high costs of granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage c...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190009057629
更新日期:2000-03-01 00:00:00
abstract::Myeloperoxidase (MPO) has been shown to catalyze the in vitro degradation of vincristine (VCR). Given that MPO is a lysosomal enzyme that can be released into the circulation by both normal activated and leukemic myeloid cells, we investigated the possibility that sera from patients with acute myeloblastic leukemia (A...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199609052426
更新日期:1996-02-01 00:00:00
abstract::Patients with higher-risk MDS have an abysmal survival record and should be started immediately on therapy, the most common of which being the hypomethylating agents, azacitidine or decitabine. Patients achieving a complete or partial response or hematologic improvement have been shown in two separate studies to have ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428194.2015.1063149
更新日期:2015-01-01 00:00:00
abstract::Central nervous system (CNS) relapse is a challenging complication in patients with diffuse large B-cell lymphoma (DLBCL). Thus, identification of the high-risk population, in whom prophylactic treatment may play a significant role, is critical. We calculated the incidence of CNS relapse and evaluated the risk factors...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2011.596966
更新日期:2011-12-01 00:00:00
abstract::Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2013.803547
更新日期:2014-02-01 00:00:00
abstract::Thirteen patients (pts) with highly refractory acute myeloid leukemia (AML) 10 pts with de novo AML and 3 with blast crisis of chronic myeloid leukemia were treated with carboplatin (CP) 150 mg/m2/day through continuous IV infusion for 7 consecutive days. Seven of them received CP at least as third or more line therap...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章
doi:10.3109/10428199409049729
更新日期:1994-10-01 00:00:00
abstract::We present an analysis of 98 consecutive patients with peripheral T-cell lymphoma (PTCL) treated over a 10-year period within Western Australia. The most common frontline therapies were CHO(E)P (47%), HyperCVAD (21%), and reduced intensity therapy or supportive care alone (19%). Median and 4-year overall survival (OS)...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2019.1637865
更新日期:2019-12-01 00:00:00
abstract::Much progress has been made in the field of allogeneic stem cell transplantation. However, one major barrier is the delay in immune recovery that can persist for months post-transplant and results in increased susceptibility to infection and relapse of malignancy. Strategies to improve immune recovery must be balanced...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190600555876
更新日期:2006-07-01 00:00:00
abstract::The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma. It irreversibly binds the chymotrypsin-like active site in the β5 subunit of the 20S proteasome. Despite impressive response rates when carfilzomib is used in combination with immunomodulatory agents in newly diagnosed multi...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2016.1214953
更新日期:2017-03-01 00:00:00
abstract::Rapamycin and its derivatives have been proposed in the treatment of leukemia based on their cytostatic effects, but their possible role in differentiation therapy is less explored. The aim of the present study was to investigate the possible beneficial effects of the combination of rapamycin and dimethyl sulfoxide (D...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2012.684351
更新日期:2012-11-01 00:00:00
abstract::Adolescents and adults with acute lymphoblastic leukemia/lymphoma (ALL) have better outcomes when treated using pediatric protocols compared with treatment using adult protocols. We reviewed the progress and outcomes of 40 adolescents and adults up to 45 years of age, from three Australian centers, treated on the inte...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章,多中心研究
doi:10.3109/10428194.2014.894191
更新日期:2014-12-01 00:00:00
abstract::The European Society for Blood and Marrow Transplantation Chronic Malignancies Working Party held a preceptorship meeting in Turin, Italy on 25-26 September 2014, to discuss the role of stem cell transplantation (SCT) in the treatment of multiple myeloma and other plasma cell disorders. Scientists and clinicians worki...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428194.2015.1131278
更新日期:2016-01-01 00:00:00
abstract::To evaluate the contribution of association studies of candidate polymorphisms to inherited predisposition to chronic lymphocytic leukemia (CLL), we conducted a systematic review and meta-analysis of published case-control studies. We identified 36 studies which reported on polymorphic variation in 19 genes and CLL ri...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,meta分析,评审
doi:10.3109/10428194.2013.800197
更新日期:2014-01-01 00:00:00
abstract::Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma in which the majority of patients present with advanced stage III or IV disease. Here we report a case of ALCL where bone marrow was the only site of disease, in a 60-year-old man with pyrexia and pancytopenia. The diagnosis of ALCL was made on detection of CD...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190400011468
更新日期:2005-03-01 00:00:00
abstract::We start a controlled clinical trial to assess efficacy and toxicity of EBVD (epirubicin, bleomycin, vinblastine and dacarbazine) with an intensive and brief program of seven drugs administered weekly for 12 weeks in previously untreated patients with advanced Hodgkin's disease. Two hundred and sixty four patients wer...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1080/1042819031000067729
更新日期:2003-08-01 00:00:00
abstract::To better define the incidence and nature of secondary chromosome anomalies in mantle cell lymphoma (MCL) carrying the t(11:14)/BCL1 rearrangement, cytogenetic and fluorescence in situ hybridization studies (FISH) were performed in 42 patients (39 classical histology, 3 blastoid variant), using 6q21, 9p21/p16, 13q14, ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190109097656
更新日期:2001-02-01 00:00:00
abstract::The association of leukocytoclastic vasculitis or dermatomyositis with malignancies has been reported. We describe a patient who developed a skin rash, histologically compatible with dermatomyositis, which during the course of the disease switched to leukocytoclastic vasculitis, which was accompanied with peripheral b...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199709114179
更新日期:1997-04-01 00:00:00
abstract::In this study we compared rates of apoptosis, survival and metabolic activity from CML peripheral blood neutrophils with peripheral blood and bone marrow neutrophils from healthy volunteer donors and studied the influence of the disease stage and of cytokines including G-CSF, GM-CSF and IL-1beta on these parameters. Q...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199709042502
更新日期:1997-03-01 00:00:00
abstract::The significant clinical activity of lenalidomide in relapsed CLL was first described several years ago. Since then the problems of tumor flare and tumor lysis have emerged, and upfront single agent studies have reported response rates that were perhaps a little disappointing. Interest in elucidating the place of lena...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2010.496017
更新日期:2010-08-01 00:00:00
abstract::The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 mon...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章
doi:10.1080/1042819021000016078
更新日期:2002-10-01 00:00:00
abstract::Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammop...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199509054750
更新日期:1995-12-01 00:00:00
abstract::Nine patients with prolonged (> 2 years) chronic phase chronic myeloid leukaemia (CML) were investigated for the presence of T-cell involvement in the leukemic clone. Pure populations of peripheral blood T-cell populations were obtained by culturing separated mononuclear cells in the presence of pokeweed mitogen and I...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199309145886
更新日期:1993-06-01 00:00:00
abstract::Respiratory viral pathogens are a common cause of morbidity in patients with hematologic malignancies. Sensitive molecular assays have increased the detection of common respiratory viruses and expanded the panel of detectable viruses. Both a rapid viral culture with direct fluorescence antibody (DFA) staining and a PC...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190902777665
更新日期:2009-04-01 00:00:00
abstract::Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199309147353
更新日期:1993-05-01 00:00:00
abstract::Genistein is one of the major isoflavones in soy products. It has been reported that genistein has apoptotic effects on certain hematological malignancies. However, so far there have been no completely comparative studies of the effect of genistein on malignant hematological diseases, especially multiple myeloma. We i...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2011.598251
更新日期:2011-12-01 00:00:00
abstract::Bullous pyoderma gangrenosum begins as a bulla, nodule or nonulcerated erythematous plaque that blisters or ulcerates to form a superficial ulcer surrounded by a hemorrhagic, bullous border, which is surrounded by a blue-gray halo. Bullous pyoderma gangrenosum is most commonly associated with hematologic malignancies,...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190500254299
更新日期:2006-01-01 00:00:00
abstract::Histological transformation of low-grade non-Hodgkin lymphoma (NHL) to diffuse large cell NHL is well recognized and is associated with a poor prognosis. We sought to determine the overall outcome and the factors that affect survival in patients with histological transformation of low-grade NHL. Between November 1979 ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190600757894
更新日期:2006-09-01 00:00:00
abstract::We describe eight cases of acute proptosis due to mantle cell lymphoma (MCL), among 26 consecutive MCL cases. The median time of onset was 29 months (range 0-102) from diagnosis. Two cases presented initially with orbital masses while five as sudden disease progression after multiple courses of chemotherapy. In each c...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190500301058
更新日期:2006-01-01 00:00:00
abstract::Forty patients, with mainly poor risk haematological malignancies, were given the new regimen FLAG, comprising fludarabine, arabinosyl cytosine and G-CSF. Twenty four patients had acute myeloid leukaemia (AML), 8 patients myelodysplastic syndrome (MDS) and a further 8 patients had a variety of other haematological mal...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199709068275
更新日期:1997-09-01 00:00:00
abstract::The hypomethylating agents azacitidine and decitabine are standard therapy for myelodysplastic syndromes (MDS), and are often used to treat patients with acute myeloid leukemia (AML) unlikely to benefit from cytotoxic chemotherapy. Switching hypomethylating agents after treatment failure is common, but this approach i...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2014.966708
更新日期:2015-06-01 00:00:00